We at BIONET are encouraged to lead the bio-industry of Taiwan and to encounter the competing-assimilating environment all over the world. By progressive communication, informative exchange, and full collaboration of human resource, R&D, capital and market on the international level, we intend to seize the advantage of globalization and to translate it into solid infrastructure as well as continuous growth of our establishment.

Rooted in Taiwan, set up a base at the great China market

BIONET has engaged in the research, development, and commercialization of products and technology, resulting in major business units of stem cell therapy and genetic testing. The core of stem cell business unit includes the original cord blood HSC, the cord MSC, and the latest development of dental pulp stem cell service. The ultimate target of which is to integrate the two major fields for building an innovative business model, offering the most advanced and complete services.

BIONET has also extended the operation throughout various areas around Asia. For example, Shanghai GeneCore Bio Technologies is a newly established subsidiary company as an initiative base of BIONET at the greater China region. GeneCore targets at exploring the market for prenatal genetic testing and pre-implantation genetic testing.

Establishment of a research center for providing PGD service in Asia

Recently BIONET had cooperated with the most representative PGD research institute of the world, Genetic Genesis Inc. (GGI), to set up the first and only PGD core laboratory in Asia. The institute is qualified to offer PGD service upon request for all clinics and hospitals in Asia. This international cooperation indicates explicitly that BIONET has been recognized as a distinguishing member of the global bio-industry.